Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review

The Lancet Oncology

Volumn 12, Issue 11, 2011, Pages 1053-1061

  Oostendorp, Linda J M ^a   Stalmeier, Peep F M ^a   Donders, A Rogier T ^a   van der Graaf, Winette T A ^a   Ottevanger, Petronella B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOXORUBICIN; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; BREAST CANCER; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DATA SYNTHESIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PALLIATIVE CARE; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 80955181061     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70045-6     Document Type: Review

References (54)

1. Ferlay J, Parkin DM, Steliarova-Foucher E Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v15-v19.
3. Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008, 19:2012-2019.
4. Saad ED, Katz A, Buyse M Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010, 28:1958-1962.
5. Amar S, Roy V, Perez EA Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 2009, 114:413-422.
6. Jones SE Considerations in treatment choice for metastatic breast cancer. Breast Cancer 2008, 15:35-39.
7. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast 2007, 16:9-10. European School of Oncology (ESO)-MBC Task Force.
8. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009, 101:1174-1181.
9. Jassem J, Carroll C, Ward SE, et al. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 2009, 45:2749-2758.
10. Moreno-Aspitia A, Perez EA Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009, 84:533-545.
11. Moreno-Aspitia A, Perez EA Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009, 31:1619-1640.
12. Saad ED, Katz A Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 2009, 20:460-464.
13. Zia MI, Siu LL, Pond GR, et al. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005, 23:6982-6991.
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
15. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
16. Pajk B, Cufer T, Canney P, et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008, 17:180-185.
17. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25:5210-5217.
18. Lin PC, Wang WS, Yang MH, et al. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. J Chin Med Assoc 2006, 69:304-309.
19. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
20. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004, 40:536-542.
21. Lee SH, Lee J, Park J, et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004, 21:223-231.
22. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003, 14:1227-1233.
23. Blum JL, Dieras V, Russo PM Lo, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92:1759-1768.
24. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17:485-493.
25. Seo HY, Lee HJ, Woo OH, et al. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer. Invest New Drugs 2011, 29:360-365.
26. Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007, 8:219-225.
27. Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006, 17:630-636.
28. Toi M, Saeki T, Aogi K, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 2005, 35:310-315.
29. Jara-Sánchez C, Martín M, García-Sáenz JA, et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer 2003, 3:399-404.
30. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001, 92:2267-2272.
31. Udom DI, Vigushin DM, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000, 36:177-182.
32. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997, 15:1395-1400.
33. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 2005, 6:55-60.
34. Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005, 90:215-221.
35. Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001, 66:83-87.
36. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004, 22:3893-3901.
37. Navelbine® (vinorelbine tartrate) injection prescribing information GlaxoSmithKline, (accessed March 10, 2011). http://www.fda.gov/ohrms/DOCKETS/ac/04/briefing/4021B1_10_Vinorelbine%20label.pdf.
38. Lilly Eli Gemzar prescribing information (accessed March 10, 2011). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020509s064lbl.pdf.
39. Ioannidis JP, Lau J Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001, 285:437-443.
40. Loke YK, Derry S Reporting of adverse drug reactions in randomised controlled trials-a systematic survey. BMC Clin Pharmacol 2001, 1:3.
41. Pitrou I, Boutron I, Ahmad N, et al. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009, 169:1756-1761.
42. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004, 141:781-788.
43. Hamilton A, Larsimont D, Paridaens R, et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 2000, 1:233-240.
44. Corle DK, Sears ME, Olson KB Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An extramural analysis. Cancer 1984, 54:1554-1561.
45. Fernández Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 2010, 36:33-42.
46. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006, 94:1610-1614.
47. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399-3406.
48. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27:2954-2961.
49. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
50. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001, 12:1247-1254.
51. Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010, 122:409-418.
52. FDA approves Ixempra for advanced breast cancer patients FDA, (accessed March 10, 2011). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109015.htm.
53. Questions and answers on recommendation for the refusal of the marketing authorization for Ixempra EMA, (accessed March 10, 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/000930/WC500014746.pdf.
54. Gerber DE Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008, 77:311-319.